Acurx Announces Publication in ASM Confirming Data on its DNA pol IIIC Inhibitor Pipeline of Antibiotics Demonstrating a Potential Microbiome-Sparing Class Effect

Acurx advances preclinical antibiotics showing microbiome benefits, but clinical milestones remain distant.

What the company is saying

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) highlights the publication of a preclinical study comparing its novel oral Pol IIIC inhibitors to linezolid, emphasizing that its compounds reduce MRSA burden while preserving gut microbiome diversity and function. The company frames these results as evidence of a new class of antibiotics with minimal gut dysbiosis, positioning itself as a leader in 'Microbiome Stewardship.' Executive Chairman Robert J. DeLuccia and lead investigator Kevin Garey, PharmD, MS, FIDSA, both stress the significance of antibiotics that spare healthy gut bacteria. The announcement underscores that Acurx’s pipeline targets Gram-positive infections classified as Serious Threats by the CDC, and that its lead candidate, ibezapolstat, is FDA QIDP and Fast Track designated. The company details planned and ongoing clinical trials (PATHFINDER and ASPIRE) for C. difficile infection, but notes these are contingent on funding and regulatory concurrence. The tone is optimistic, focusing on scientific innovation and regulatory engagement, but does not address commercial timelines or financial performance.

What the data suggests

The announcement provides detailed epidemiological figures: the CDC estimates approximately 323,700 hospital MRSA cases and 10,600 MRSA deaths annually in the US, with MRSA accounting for 52% of all hospital infections in a recent surveillance study. C. difficile is estimated at 500,000 to 600,000 annual US cases with 30,000 deaths and a mortality rate of 9.3%. Recurrence rates for CDI treatments are 20% to 40% among 150,000 patients, with rCDI incidence after fidaxomicin at 4% to 19.5% and after vancomycin at 17% to 27%. The preclinical murine model used a final inoculum of 1.8 × 10^5 CFU per mouse thigh, and all tested Pol IIIC inhibitors reduced MRSA burden while maintaining gut microbial diversity, unlike linezolid. Clinical trial plans are specific: PATHFINDER is a 20-patient pilot for multiply-recurrent CDI, and ASPIRE is a non-inferiority Phase 3 trial with 550 subjects, randomized 1:1 to ibezapolstat or vancomycin. No financial data, cash position, or funding commitments are disclosed. The evidence supports preclinical efficacy and regulatory engagement, but all clinical and commercial benefits remain unproven and dependent on future trial outcomes and funding.

Analysis

The announcement is positive in tone, highlighting preclinical success and regulatory progress, but most key claims are forward-looking and contingent on future events. While the publication of preclinical results is a realised milestone, the majority of the narrative focuses on planned or aspirational clinical trials (PATHFINDER, ASPIRE) and potential regulatory filings, all of which are subject to funding and further data. The benefits described (e.g., clinical impact, NDA submission, paradigm shift in rCDI treatment) are long-term and depend on successful completion of large, capital-intensive trials that have not yet begun or are awaiting resources. There is no disclosure of financial results, cash position, or committed funding for these trials, and no immediate earnings impact is expected. The language inflates the signal by implying readiness for pivotal trials and broad clinical applicability, despite the current stage being preclinical or early clinical. The data supports preclinical efficacy and regulatory engagement, but not imminent commercial or financial outcomes.

Risk flags

• ●The company’s clinical progress is highly dependent on securing additional funding, as the pivotal ASPIRE Phase 3 trial will only proceed when sufficient resources are available. This introduces significant financial and execution risk, as there is no disclosed cash position or partnership to guarantee trial initiation.
• ●All clinical and commercial claims are forward-looking and contingent on successful trial outcomes, regulatory approval, and FDA concurrence on single-trial NDA submission. Failure at any stage would materially delay or derail the program.
• ●The announcement does not provide any financial data, such as cash runway or burn rate, making it impossible to assess the company’s ability to sustain operations through the planned clinical milestones. This lack of transparency increases uncertainty for investors.

Bottom line

Acurx Pharmaceuticals’ preclinical data show that its Pol IIIC inhibitors reduce MRSA burden while preserving gut microbiome health, differentiating them from linezolid in animal models. The company is pursuing ambitious clinical development for ibezapolstat in C. difficile infection, with a small PATHFINDER pilot underway and a larger ASPIRE Phase 3 trial planned but not yet funded. The epidemiological need is clear, with hundreds of thousands of US cases and high recurrence rates, but all clinical and commercial value is still several years and multiple hurdles away. No financial or operational data are disclosed, so investors have no visibility into funding sufficiency or near-term catalysts. The most important takeaway is that while the science is promising, the path to value realization is long, capital-intensive, and uncertain until clinical and financial milestones are met.

Announcement summary

(NASDAQ:ACXP) Acurx Pharmaceuticals, Inc. announced the publication of a head-to-head preclinical study comparing gut microbiome changes from novel oral PolC (pol IIIC) inhibitors to linezolid in a murine neutropenic thigh infection model. The study, published in ASM Microbiology Spectrum, found that structural molecular modification of molecules related to ibezapolstat improved solubility and systemic exposure of new Pol IIIC inhibitors, with all three tested compounds reducing MRSA burden in the mouse model. The Pol IIIC inhibitors maintained high gut microbial diversity and preserved microbiome metabolic function, in contrast to the marked disruption caused by linezolid. The compounds specifically preserved anaerobic microbiome components and metabolism, while linezolid induced depletion and disruption of healthy anaerobic bacterial communities. Acurx's DNA pol IIIC inhibitor preclinical product candidates are FDA QIDP and Fast-Track eligible and target Gram-positive infections classified as Serious Threat priorities by the CDC. The murine thigh MRSA infection model used MRSA strain BAA-1717 (USA 300) with a final inoculum of 1.8 × 10^5 CFU per mouse thigh, and antibiotic treatment began 1 hour post-infection. The study was conducted at NeoSome Life Sciences under protocol number NLS24-011. Kevin Garey, PharmD, MS, FIDSA, Principal Investigator for microbiology and microbiome aspects of Acurx's DNA pol IIIC program and Robert L. Boblitt Endowed Professor at the University of Houston College of Pharmacy, is the lead author. Robert J. DeLuccia, Executive Chairman of Acurx, commented on the company's focus on developing innovative narrow-spectrum antibiotics with minimal gut dysbiosis. Acurx's preclinical compounds have clinical applications for infections caused by MRSA, including ABSSI, hospital-acquired and ventilator-acquired bacterial pneumonia, bacteremia with or without sepsis and/or endocarditis, bone and joint and diabetic foot infections, and B. anthracis (anthrax). The CDC estimates approximately 323,700 hospital cases of MRSA infections annually in the US, with about 10,600 deaths. In a recent CDC surveillance study, MRSA accounted for 52% of all infections in hospitalized patients in the US. Ibezapolstat for the treatment of C. difficile Infection (CDI) is ready to advance to Phase 3 international pivotal trials. The PATHFINDER clinical trial is a pilot trial in approximately 20 patients with multiply-recurrent CDI (at least three episodes over the past 12 months) and will support filing of a U.S. NDA based on a single Phase 3 trial. Participants will be treated with IBZ for 14 days and assessed for Clinical Cure (Day 16), Sustained Clinical Cure (Day 42), rate of CDI recurrence (to Week 24), and Extended Clinical Cure (to Week 24). The planned ASPIRE trial is a non-inferiority design with approximately 550 subjects in the mITT population, randomized 1:1 to either ibezapolstat or standard-of-care vancomycin, to be conducted when sufficient resources are available. Acurx previously announced a successful Type C Meeting with FDA on July 13, 2026, regarding ibezapolstat's Phase 3 clinical program and NDA scope. The FDA stated it is open to further discussion at a Pre-NDA Meeting about submitting an NDA with only a single Phase 3 trial, depending on the totality of clinical and supportive data. If the IBZ-ASPIRE trial does not meet criteria, a second trial consistent with the agreement reached at the EOP2 meeting on April 27, 2024, is recommended. Ibezapolstat is a novel, orally administered antibiotic, the first of a new class of DNA polymerase IIIC inhibitors, and was designated by the FDA as a Qualified Infectious Disease Product (QIDP) in June 2018 and granted Fast Track designation in 2019. The CDC estimates C. difficile approaches 500,000 infections annually in the US, with approximately 30,000 deaths. The recurrence rate for antibiotics currently used to treat CDI is between 20% and 40% among approximately 150,000 patients treated. The annual incidence of CDI in the US is believed to approach 600,000 infections with a mortality rate of approximately 9.3%. In recent studies, rCDI incidence ranges from 4% to 19.5% following treatment with fidaxomicin and 17% to 27% following treatment with vancomycin.

Disagree with this article?